Mistaking 2C-P for 2C-B: What a Difference a Letter Makes.
Adrian Stoller, Patrick C. Dolder, Michael Bodmer, Felix Hammann, Katharina Rentsch, Aristomenis K Exadaktylos, Matthias E. Liechti, Evangelia Liakoni
Journal of Analytical Toxicology 2017 DOI: 10.1093/jat/bkw108 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | 19-year-old male |
| Keywords | Chemical structure variation Drug potency Synthetic drugs Adverse drug effects |
| Citations | 19 |
| Key findings | The substance sold as 2C-B was actually the more potent 2C-P, with an estimated elimination half-life of 19 hours, highlighting how structural differences in 2C drugs affect potency and duration of action. |
Abstract
2,5-Dimethoxy-4(n)-propylphenethylamine (2C-P) is a synthetic phenethylamine derivative belonging to the large family of the so-called 2C drugs. These compounds can differ significantly in receptor affinity, potency and duration of action, and an important structural difference is the ligand in the 4 position of the phenyl ring, such as propyl in 2C-P or bromine in 2,5-dimethoxy-4-bromophenethylamine (2C-B). The 2C drugs are known for their hallucinogenic properties. We present a case of a 19-year-old male admitted to the emergency department with severe hallucinations, mydriasis, tachycardia, agitation and confusion following the use of a substance sold as 2C-B. By using liquid chromatography-mass spectrometry, the more potent substance 2C-P was detected and quantified. On the basis of two blood sample concentrations, the estimated elimination half-life was 19 h. This case report illustrates and discusses the differences in potency and duration of action of 2C drugs.
Citations in the library
Cited by 10
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology May 15, 2018
- Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics Experimental Neurology June 4, 2021
- Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. Journal of Psychopharmacology September 1, 2019
- Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. Drug Testing and Analysis February 1, 2019
and 5 more in the library
Cites 7
- Clinical toxicology of newer recreational drugs Clinical Toxicology October 1, 2011
- Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology December 1, 2015
- Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling Swiss Medical Weekly January 11, 2015
- Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology January 5, 2005
- Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochemical Pharmacology January 15, 2007
and 2 more in the library